717 related articles for article (PubMed ID: 12699402)
1. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.
Keating GM; Noble S
Drugs; 2003; 63(10):1021-51. PubMed ID: 12699402
[TBL] [Abstract][Full Text] [Related]
2. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B.
Adkins JC; Wagstaff AJ
BioDrugs; 1998 Aug; 10(2):137-58. PubMed ID: 18020591
[TBL] [Abstract][Full Text] [Related]
3. The immunogenicity in healthy infants and efficiency to prevent mother to child transmission of Hepatitis B virus of a 10μg recombinant yeast-derived Hepatitis B vaccine (Hep-KSC).
Zhu FC; Sun KX; Pan HX; Yang ZH; Lu Y; Liang ZL; Liang XF; Wang FZ; Zeng Y; Li J
Vaccine; 2016 May; 34(24):2656-62. PubMed ID: 27113166
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.
Young MD; Gooch WM; Zuckerman AJ; Du W; Dickson B; Maddrey WC
J Med Virol; 2001 Jul; 64(3):290-8. PubMed ID: 11424117
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India.
Velu V; Nandakumar S; Shanmugam S; Jadhav SS; Kulkarni PS; Thyagarajan SP
World J Gastroenterol; 2007 Jun; 13(22):3084-9. PubMed ID: 17589924
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines.
Coates T; Wilson R; Patrick G; André F; Watson V
Clin Ther; 2001 Mar; 23(3):392-403. PubMed ID: 11318074
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules.
Agladioglu S; Beyazova U; Camurdan AD; Sahin F; Atak A
Infection; 2010 Aug; 38(4):269-73. PubMed ID: 20512395
[TBL] [Abstract][Full Text] [Related]
12. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
Jafarzadeh A; Zarei S; Shokri F
Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.
el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN
Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age.
Greenberg DP; Vadheim CM; Wong VK; Marcy SM; Partridge S; Greene T; Chiu CY; Margolis HS; Ward JI
Pediatr Infect Dis J; 1996 Jul; 15(7):590-6. PubMed ID: 8823852
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
[TBL] [Abstract][Full Text] [Related]
17. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
[TBL] [Abstract][Full Text] [Related]
19. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
Gunn TR; Bosley A; Woodfield DG
N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates.
Bassily S; Kotkat A; Gray G; Hyams KC; Brown FM; Imam IZ; Arthur R
Am J Trop Med Hyg; 1995 Oct; 53(4):419-22. PubMed ID: 7485697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
